11基因RNA检测在I-III期皮肤黑色素瘤存档组织中的预后价值
本研究在291例I-III期皮肤黑色素瘤患者的福尔马林固定石蜡包埋原发肿瘤组织中,验证11基因表达谱检测的预后价值。预设算法将患者分为低评分组和高评分组,低评分组5年无病生存率和黑色素瘤特异性生存率分别为95%和99%,高评分组分别为78%和88%。多因素Cox回归显示仅11基因表达谱、肿瘤厚度和年龄与黑色素瘤特异性生存率独立相关。
要点
- 11基因表达谱是黑色素瘤患者的独立预后预测因子。
- 评分≤0可识别10年生存概率远超90%的患者群体。
- 该信息可用于辅助治疗决策。
核心结论
- 11基因表达谱检测已被验证为黑色素瘤患者结局的独立预测因子。
- 使用11基因表达谱评分截断值≤0,可识别10年生存概率远超90%的患者群体。
研究设计与样本
- 对291例I-III期皮肤黑色素瘤患者的福尔马林固定石蜡包埋原发肿瘤组织进行11个前瞻性选定基因的逆转录聚合酶链反应检测。
- 使用8个预后基因和3个参考基因的表达水平,通过预设算法计算数值评分(-0.84至3.53),并将患者分配至预设风险组(低评分与高评分)以评估黑色素瘤特异性生存率。
主要发现
- 164例患者被分配至高评分组,其5年无病生存率和黑色素瘤特异性生存率分别为78%和88%。
- 连续回归分析显示黑色素瘤特异性生存概率随评分增加而降低。
- 多因素Cox回归中,仅11基因表达谱、肿瘤厚度和年龄与黑色素瘤特异性生存率统计学相关(p值分别为0.0068、0.002和0.0159)。
关键数值与推荐
- 11基因表达谱评分范围为-0.84至3.53。
- 评分截断值≤0可识别10年生存概率远超90%的患者群体。
临床怎么用
- 该检测信息可用于辅助治疗决策,特别是潜在辅助治疗的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to validate the results of an 11-gene expression profiling (GEP) assay which aims to improve the precision of individual prognosis beyond conventional American Joint Committee on Cancer staging for patients with cutaneous melanoma. METHODS: The reverse transcriptase polymerase chain reaction test of 11 prospectively selected genes was performed on 291 formalin-fixed, paraffin-embedded primary tumours of patients with stage I-III cutaneous melanoma. The expression levels of eight prognostic and three reference genes were used in a predefined algorithm to calculate a numerical score (-0.84 to 3.53) and then assign each patient to a preselected risk group (low versus high score) for melanoma-specific survival (MSS). RESULTS: One hundred twenty-seven patients were allocated to the low-score group, with a corresponding five-year disease-free survival (DFS) and MSS of 95% and 99%, respectively. 164 patients were allocated to the high-score group, with a corresponding five-year DFS and MSS of 78% and 88%. Continuous regression analysis demonstrated decreasing MSS probabilities with increasing scores. In a multivariate cox regression, only the 11-GEP, tumour thickness and age were statistically associated with MSS (p = 0.0068, 0.002 and 0.0159). CONCLUSIONS: The 11-GEP has been validated as an independent predictor of outcome for melanoma patients. More specifically, using an 11-GEP score cut-off of ≤0, the assay can identify patient cohorts with 10-year survival probabilities well above 90%. This information may be used in the decision-making for a potential adjuvant therapy.
引用
- Gambichler T, Tsagoudis K, Kiecker F, et al. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. Eur J Cancer. 2020. PMID: 33278769. doi:10.1016/j.ejca.2020.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。